Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Of ...

Company Overview - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [1] - The company's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [1] Investor Engagement - Management will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 5, 2025, and the H.C. Wainwright Global Investment Conference on September 9, 2025 [3] - The Morgan Stanley Global Healthcare Conference is scheduled for September 10, 2025, where a fireside chat will take place [3] - These events will include one-on-one meetings and webcasts accessible via the Altimmune website [3]

Core Points - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [3] - The company will report its second quarter 2025 financial results on August 12, 2025, and will host a conference call at 8:30 am E.T. to discuss these results and provide a business update [1] - The lead program of Altimmune is pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [3] Company Information - Altimmune is engaged in the development of therapeutics specifically targeting liver and cardiometabolic diseases [3] - The company’s lead therapeutic candidate, pemvidutide, is designed to address multiple conditions related to metabolic dysfunction and alcohol use [3] - For further information, Altimmune maintains an Investor Relations website where financial results and updates can be accessed [1][2]